Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Suttorp, Marit M ^a   Hoekstra, Tiny ^a   Rotmans, Joris I ^a   Ott, Ilka ^b   Mittelman, Moshe ^c   Krediet, Raymond T ^d   Dekker, Friedo W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cohort study; Erythropoietin; ESA Resistance; Hemodialysis; Mortality; Peritoneal dialysis

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NETHERLANDS; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ANEMIA; COHORT STUDIES; COMORBIDITY; DRUG RESISTANCE; FEMALE; HEMATINICS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PERITONEAL DIALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884525110     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-200     Document Type: Article

References (42)

1. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Nephrol Dial Transplant 2004 19 121 132 10.1093/ndt/gfg458 14671047 (Pubitemid 38072623)
2. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D, Kidney Int 2010 78 215 223 10.1038/ki.2010.108 20428102
3. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW, N Engl J Med 1987 316 73 78 10.1056/NEJM198701083160203 3537801 (Pubitemid 17052741)
4. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Singh A, Semin Dial 2009 22 64 69 10.1111/j.1525-139X.2008.00518.x 19175537
5. Erythropoiesis-stimulating agent hyporesponsiveness. Johnson DW, Pollock CA, Macdougall IC, Nephrology (Carlton) 2007 12 321 330 10.1111/j.1440-1797. 2007.00810.x (Pubitemid 47075419)
6. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Lopez-Gomez JM, Portoles JM, Aljama P, Kidney Int Suppl 2008 74 75 S81
7. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Nephrol Dial Transplant 2011 26 2641 2648 10.1093/ndt/gfq802 21325348
8. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, et al. Am J Kidney Dis 2012 59 108 116 10.1053/j.ajkd.2011.07.014 21890255
9. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. KDOQI; National Kidney Foundation, Am J Kidney Dis 2006 47 11 S145 16678659
10. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Clin J Am Soc Nephrol 2008 3 1077 1083 10.2215/CJN.04601007 18417744
11. Epoetin requirements predict mortality in hemodialysis patients. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ, Am J Kidney Dis 2004 44 866 876 15492953 (Pubitemid 39445919)
12. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. N Engl J Med 2010 363 1146 1155 10.1056/NEJMoa1005109 20843249
13. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Kainz A, Mayer B, Kramar R, Oberbauer R, Nephrol Dial Transplant 2010 25 3701 3706 10.1093/ndt/gfq287 20507852
14. Stichting Renine, Statistics, percentage peritoneal dialysis [ https://www.renine.nl/static?id=pdprop&render=png ] accessed August 14, 2013
15. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP, et al. Am J Nephrol 2012 35 198 208 10.1159/000335685 22286821
16. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, et al. Nephrol Dial Transplant 2001 16 1120 1129 10.1093/ndt/16.6.1120 11390709 (Pubitemid 32547364)
17. Reliability of the 7-point subjective global assessment scale in assessing nutritional status of dialysis patients. Visser R, Dekker FW, Boeschoten EW, Stevens P, Krediet RT, Adv Perit Dial 1999 15 222 225 10682107
18. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Watson PE, Watson ID, Batt RD, Am J Clin Nutr 1980 33 27 39 6986753 (Pubitemid 10141676)
19. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Nephrol Dial Transplant 2004 19 Suppl 2 i1 ii47 15206425
20. Review: a gentle introduction to imputation of missing values. Donders AR, van der Heijden GJ, Stijnen T, Moons KG, J Clin Epidemiol 2006 59 1087 1091 10.1016/j.jclinepi.2006.01.014 16980149 (Pubitemid 44374314)
21. UK Renal Registry 13th Annual Report (December 2010): Chapter 9: Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2009: national and centre-specific analyses. Gilg J, Webb L, Feest T, Fogarty D, Nephron Clin Pract 2011 119 Suppl 2 149 c177 21894032
22. Predictors of the rate of decline of residual renal function in incident dialysis patients. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, Kidney Int 2002 62 1046 1053 10.1046/j.1523-1755.2002.00505.x 12164889 (Pubitemid 35316736)
23. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. McGonigle RJ, Husserl F, Wallin JD, Fisher JW, Kidney Int 1984 25 430 436 10.1038/ki.1984.35 6727138 (Pubitemid 14142833)
24. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Besarab A, Reyes CM, Hornberger J, Am J Kidney Dis 2002 40 439 446 10.1053/ajkd.2002.34881 12200793 (Pubitemid 34971270)
25. Breast cancer trial with erythropoietin terminated unexpectedly. Leyland-Jones B, Lancet Oncol 2003 4 459 460 10.1016/S1470-2045(03)01163-X 12901958 (Pubitemid 37009952)
26. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Lancet 2003 362 1255 1260 10.1016/S0140-6736(03)14567-9 14575968 (Pubitemid 37324251)
27. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, et al. Clin Lung Cancer 2011 12 62 69 10.3816/CLC.2011.n.009 21273182
28. Erythropoietin: the swinging pendulum. Oster HS, Neumann D, Hoffman M, Mittelman M, Leuk Res 2012 36 939 944 10.1016/j.leukres.2012.04.017 22579365
29. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. N Engl J Med 1998 339 584 590 10.1056/NEJM199808273390903 9718377 (Pubitemid 28385655)
30. Correction of anemia with epoetin alfa in chronic kidney disease. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. N Engl J Med 2006 355 2085 2098 10.1056/NEJMoa065485 17108343 (Pubitemid 44749317)
31. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. N Engl J Med 2006 355 2071 2084 10.1056/NEJMoa062276 17108342 (Pubitemid 44749316)
32. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. N Engl J Med 2009 361 2019 2032 10.1056/NEJMoa0907845 19880844
33. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of medicare hemodialysis patients. Weinhandl ED, Gilbertson DT, Collins AJ, Am J Nephrol 2011 34 298 308 10.1159/000330693 21829009
34. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA, Pharmacoepidemiol Drug Saf 2009 18 932 940 10.1002/pds.1799 19572312
35. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Wang O, Kilpatrick RD, Critchlow CW, Ling X, Bradbury BD, Gilbertson DT, et al. Clin J Am Soc Nephrol 2010 5 182 188 10.2215/CJN.03040509 20019122
36. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA, Clin J Am Soc Nephrol 2009 4 638 644 10.2215/CJN.05071008 19261818
37. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Singh AK, Curr Opin Nephrol Hypertens 2010 19 420 424 10.1097/MNH.0b013e32833cf1d6 20689425
38. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Gunnell J, Yeun JY, Depner TA, Kaysen GA, Am J Kidney Dis 1999 33 63 72 10.1016/S0272-6386(99)70259-3 9915269 (Pubitemid 29031210)
39. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD, Am J Kidney Dis 2003 42 761 773 10.1016/S0272-6386(03)00915-6 14520627 (Pubitemid 37187377)
40. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR, Clin J Am Soc Nephrol 2010 5 576 581 10.2215/CJN.04710709 20110344
41. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Am J Kidney Dis 2009 53 823 834 10.1053/j.ajkd.2008.12.040 19339087
42. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Kidney Int 2008 74 791 798 10.1038/ki.2008.295 18596733